Cortistatin: Dosing Protocols

Preclinical Research Status#

Cortistatin is an endogenous neuropeptide that has not entered human clinical trials. All dosing information below is derived from animal studies and is provided for research context only. There are no established human dosing protocols for cortistatin.

Research Dosing in Animal Models#

Sleep Studies#

In the foundational sleep research by de Lecea et al. (Nature 1996) and Bourgin et al. (Eur J Neurosci 2007):

• Route: Intracerebroventricular (ICV) administration in rats
• Dose range: 0.1-1.0 nmol CST-14
• Effects: Dose-dependent promotion of deep slow-wave sleep with enhanced EEG synchronization
• Onset: Within minutes of ICV administration
• Duration: Sleep-promoting effects lasted several hours

ICV administration delivers the peptide directly to the cerebrospinal fluid, bypassing the blood-brain barrier. This route is used in preclinical neuroscience research but is not applicable to clinical use.

Anti-inflammatory Studies#

In the inflammatory bowel disease research by Gonzalez-Rey et al. (PNAS 2006):

• Route: Intraperitoneal (IP) injection in mice
• Dose: 1-5 nmol CST-14 daily
• Duration: Treatment for 5-10 days during active colitis
• Effects: Significant amelioration of colitis severity, reduced inflammatory cytokines, prevention of disease recurrence

In sepsis studies:

• Route: IP injection in mice
• Dose: 5 nmol CST-14 (single dose or repeated)
• Effects: Protection against lethal endotoxemia, reduced inflammatory mediator production

Limitations of Preclinical Dosing Data#

Several factors prevent direct translation of animal dosing to human use:

1. Route of administration: ICV and IP routes used in research are not practical for clinical application
2. Blood-brain barrier: Cortistatin does not efficiently cross the BBB, limiting systemic administration for CNS effects
3. Short half-life: Rapid proteolytic degradation in vivo requires frequent dosing or structural modification
4. Species differences: Metabolic rates and receptor expression patterns differ between rodents and humans
5. No human PK data: Pharmacokinetic parameters in humans have not been determined

Therapeutic Development Challenges#

The short half-life and poor BBB penetration of native cortistatin present significant barriers to clinical development. Research approaches to address these include:

• Structural analogs: A cortistatin analog with improved selectivity was reported in Nature Communications (2021), designed to retain immunomodulatory activity while improving pharmacokinetic properties
• Targeted delivery: Nanoparticle or peptide-drug conjugate approaches could improve delivery to target tissues
• Receptor-selective analogs: Developing analogs that selectively activate cortistatin-specific pathways (e.g., GHSR-1a) while avoiding somatostatin receptor cross-reactivity

Dosing Context#

Cortistatin belongs to the Sleep category of research peptides. Dosing protocols for Cortistatin are derived from available clinical trial data. These protocols are provided for research reference only and do not constitute medical advice. Actual dosing decisions should be made by qualified healthcare providers based on individual patient factors.

Research Protocols#

The following dosing protocols have been documented in clinical research for Cortistatin:

Preclinical Sleep Research (Intracerebroventricular)#

Dose: In rat studies, 0.1-1.0 nmol cortistatin-14 administered ICV produced dose-dependent increases in slow-wave sleep. These are research doses not applicable to human use.

Frequency: Single ICV injection in preclinical studies

Duration: Acute single-dose studies

ICV administration bypasses the blood-brain barrier. Sleep effects observed within minutes and lasted several hours. Not a clinically applicable route.

Preclinical Anti-inflammatory Research (Systemic)#

Dose: In mouse colitis models, cortistatin was administered at 1-5 nmol IP daily. In sepsis models, single-dose cortistatin at 5 nmol IP provided significant protection against endotoxemia.

Frequency: Daily IP injection in preclinical models

Duration: 5-10 days in colitis studies

Systemic administration was effective for peripheral inflammatory conditions. Research doses are species-specific and not translatable to human dosing.

Reconstitution and Preparation#

Research-grade cortistatin-14 is typically supplied as a lyophilized powder. Reconstitute in sterile water or physiological saline. Store reconstituted peptide at -20 degrees C in aliquots to avoid freeze-thaw cycles.

Storage Requirements#

Lyophilized powder should be stored at -20 degrees C, protected from light and moisture. Reconstituted solutions should be aliquoted and stored at -20 degrees C. Avoid repeated freeze-thaw cycles.

Related Reading#

• Cortistatin overview and research guide
• Cortistatin side effects profile
• Cortistatin research evidence